Your email has been successfully added to our mailing list.

×
-0.00688468158347674 -0.00688468158347674 -0.00688468158347674 -0.00688468158347674 -0.00688468158347674 -0.00688468158347674 -0.00688468158347674 -0.00688468158347674
Stock impact report

Hikma wins right to market Roche drug copy in Middle East and North Africa [Reuters]

HIKMA PHARMS PLC S/ADR (HKMPY) 
NASDAQ:AMEX Investor Relations: hikma.com/en/investors.html
Company Research Source: Reuters
Hikma wins right to market Roche drug copy in Middle East and North Africa | Reuters Reuters Staff 2 Min Read (Reuters) - Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche’s blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday. The Jordan-based drugmaker agreed on the licensing deal with Celltrion to market the South Korea-based biopharmaceutical firm’s Truxima, a copy of Roche’s blockbuster blood cancer medicine, also known as MabThera. Truxima, the first biosimilar cancer drug to hit the European market in February, is used to treat patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and microscopic polyangiitis. Hikma, which makes and markets branded and non-branded generic and injectable drugs in more than 50 countries including Britain, has been hit by higher pricing pressures in the generic industry and has lowered revenue fore Show less Read more
Impact Snapshot
Event Time:
HKMPY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HKMPY alerts
Opt-in for
HKMPY alerts

from News Quantified
Opt-in for
HKMPY alerts

from News Quantified